RecruitingNot Applicable

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

United States, Canada, Israel20,000 participantsStarted 2015-07

Plain-language summary

Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.

Who can participate

Age range

21 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Onset of rheumatic disease prior to age 16 years for JIA and onset prior to age 19 years for all other rheumatic diseases (see appendix A).
. Subject (and/or parent/legal guardian when required) is able to provide written informed consent and willing to comply with study procedures.
. Subject and/or parent/legal guardian is willing to be contacted in the future by study staff.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Prospectively collect essential data elements from children, adolescents and young adults with pediatric rheumatic diseases

Timeframe: Approximately 10 years

Evaluate the safety of therapeutic agents in persons with pediatric onset rheumatic diseases

Timeframe: Approximately 10 years

Trial details

NCT IDNCT02418442

SponsorDuke University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-06

Contact for this trial

Mara L Becker, MD, MSCE

(919) 419-5032 mara.becker@duke.edu

View on ClinicalTrials.gov More Rheumatic Joint Disease trials